Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy

Yu, Irene S.; Cheung, Winson Y.

doi:10.1155/2018/9450754

Cited by 47Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy

Open access

Yu, Irene S., Cheung, Winson Y.·2018·Canadian Journal of Gastroenterology and Hepatology

DOI 10.1155/2018/9450754PMC PMC6241232

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer is the second most common malignancy diagnosed in Canada. Despite declining incidence and mortality rates in recent years, there is still a significant number of cases that are metastatic at presentation. Fluoropyrimidine-based chemotherapy was the backbone of colorectal cancer treatment, but the addition of irinotecan and oxaliplatin to form combination regimens has significantly improved overall survival. In the past decade, the development of novel biologic agents including therapies directed against vascular endothelial growth factor and epidermal growth factor receptor has further altered the landscape of metastatic colorectal cancer treatment. However, clinical trials have demonstrated that not all patients respond to these therapies similarly and consideration must be given to individual patient- and tumor-related factors. A more tailored and biomarker driven approach to treatment selection can optimize outcomes and avoid unnecessary adverse effects. In this review article, we offer a comprehensive overview of the panel of clinical- and tumor-associated characteristics that influence treatment decisions in metastatic colorectal cancer and how this sets the foundation for a more personalized treatment strategy in oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1155/2018/9450754

Cites

108 of 110 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The current clinical nursing mode of homogeneous medical concept combined with focused solution mode lacks the ability to perceive the patient's physiological state and enhance the patient's sense of self-control.
“However, the current clinical nursing mode of homogeneous medical concept combined with focused solution mode lacks the ability to perceive the patient’s physiological state and enhance the patient’s sense of self-control [8].”
From Mindfulness intervention, homogeneous medical concept, and concentrated solution nursing for colorectal cancer patients: a retrospective study (2024) · cites this paper as [8]
The Introduction and Conclusion discuss tailoring systemic therapy for metastatic colorectal cancer, while §7 (Elderly Population) discusses assessing patients’ fitness for treatment. Searches for the named nursing mode and for patients’ physiological awareness or sense of self-control found no passage addressing the claimed limitation. (LLM, conf=0.76)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084 · see citing works
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432 · see citing works
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · see citing works
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · see citing works
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C. D., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,004 · see citing works
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · see citing works
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · see citing works
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · see citing works
Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · see citing works
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Alberts, S. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,251 · see citing works
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works
Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · see citing works
Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society
Wolf, A. M. D., Fontham, E. T. H., Church, T. R., Flowers, C. R., Guerra, C. E., LaMonte, S. J., Etzioni, R., McKenna, M. T., Oeffinger, K. C., Shih, Y. T., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21457 · Cited by 1,944 · see citing works
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,916 · see citing works
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · see citing works
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · see citing works
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Douillard, J., Siena, S., Cassidy, J., Tabernero, J. M., Burkes, R. L., Barugel, M. E., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,802 · see citing works
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · see citing works
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518 · see citing works
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,456 · see citing works
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431 · see citing works
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · see citing works
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,229 · see citing works
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167 · see citing works
Use of comprehensive geriatric assessment in older cancer patients:
Extermann, M., Aapro, M., Bernabei, R., Cohen, H. J., Droz, J.-P., Lichtman, S., Mor, V., Monfardini, S., Repetto, L., Sørbye, L., et al. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.06.003 · Cited by 1,098 · see citing works
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · see citing works
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960 · see citing works
Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · see citing works
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Poon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., & Tschetter, L. K. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1407 · Cited by 887 · see citing works
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O. M., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 798 · see citing works
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations
Decoster, L., Van Puyvelde, K., Mohile, S., Wedding, U., Basso, U., Colloca, G., Rostoft, S., Overcash, J., Wildiers, H., Steer, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu210 · Cited by 794 · see citing works
Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 778 · see citing works
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772 · see citing works
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734 · see citing works
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer
Petrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P., Passalacqua, R., Sgroi, G., & Barni, S. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4227 · Cited by 734 · see citing works
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration
Talarico, L., Chen, G., & Pazdur, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.175 · Cited by 727 · see citing works
Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival
Benedix, F., Kube, R., Meyer, F. P., Schmidt, U., Gastinger, I., & Lippert, H. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181c703a4 · Cited by 714 · see citing works
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · see citing works
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
Scheithauer, W., Rosen, H., Kornek, G. V., Sebesta, C., & Depisch, D. (1993) · BMJ · doi:10.1136/bmj.306.6880.752 · Cited by 654 · see citing works
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646 · see citing works
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
Cunningham, D., Láng, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D. J., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 641 · see citing works
Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606 · see citing works
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
Petrelli, N. J., Douglass, H. O., Herrera, L. R., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R. A., Green, M. D., & Muggia, F. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1419 · Cited by 550 · see citing works
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 535 · see citing works
The Relevance of Primary Tumour Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials
Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534 · see citing works
Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study
Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506 · see citing works
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · see citing works
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Seymour, M., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, S. F., O'Mahony, M. S., Maughan, T., Parmar, M., & Langley, R. E. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60399-1 · Cited by 420 · see citing works
Clinical Relevance of KRAS in Human Cancers
Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010) · BioMed Research International · doi:10.1155/2010/150960 · Cited by 406 · see citing works
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Kopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H., Magliocco, A. M., Maru, D. M., Yan, Y., Lanman, R. B., Manyam, G. C., Hong, D. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 390 · see citing works
Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer?
Yuhara, H., Steinmaus, C., Cohen, S. E., Corley, D. A., Tei, Y., & Buffler, P. A. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.301 · Cited by 374 · see citing works
Impact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer
Meyerhardt, J. A., Catalano, P. J., Haller, D. G., Mayer, R. J., Macdonald, J. S., Benson, A. B., & Fuchs, C. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.125 · Cited by 374 · see citing works
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
Brule, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R. P. W., Tebbutt, N. C., Underhill, C. R., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 335 · see citing works
Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA binding
Ta, L. E., Espeset, L., Podratz, J. L., & Windebank, A. J. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.04.010 · Cited by 327 · see citing works
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., Guillebon, É. D., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S. M., & Tartour, É. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 323 · see citing works
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319 · see citing works
The changing prevalence of comorbidity across the age spectrum
Piccirillo, J. F., Vlahiotis, A., Barrett, L. B., Flood, K. L., Spitznagel, E. L., & Steyerberg, E. W. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.013 · Cited by 311 · see citing works
Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis
Corley, D. A., Jensen, C. D., Quinn, V. P., Doubeni, C. A., Zauber, A. G., Lee, J. K., Schottinger, J. E., Marks, A. R., Zhao, W. K., Ghai, N. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3634 · Cited by 296 · see citing works
Surveillance after curative treatment for colorectal cancer
van der Stok, E. P., Spaander, M. C. W., Grünhagen, D. J., Verhoef, C. K., & Kuipers, E. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.199 · Cited by 273 · see citing works
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Allegra, C. J., Rumble, R. B., Hamilton, S. R., Mangu, P. B., Roach, N., Hantel, A., & Schilsky, R. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9674 · Cited by 267 · see citing works
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
Hurwitz, H. I., Tebbutt, N. C., Kabbinavar, F. F., Giantonio, B. J., Guan, Z.-Z., Mitchell, L., Waterkamp, D., & Tabernero, J. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0107 · Cited by 237 · see citing works
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed Central · doi:10.3748/wjg.v18.i37.5171 · Cited by 230 · see citing works
Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer
Wille-Jørgensen, P., Syk, I., Smedh, K., Laurberg, S., Nielsen, D. T., Petersen, S. H., Renehan, A. G., Horváth–Puhó, E., Påhlman, L., Sørensen, H. T., et al. (2018) · JAMA · doi:10.1001/jama.2018.5623 · Cited by 230 · see citing works
Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 228 · see citing works
Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes
Rafacho, A., Ortsäter, H., Nadal, A., & Quesada, I. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0373 · Cited by 216 · see citing works
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
Sargent, D. J., Köhne, C. H., Sanoff, H. K., Bot, B. M., Seymour, M. T., de Gramont, A., Porschen, R., Saltz, L. B., Rougier, P., Tournigand, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2879 · Cited by 196 · see citing works
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
Grasselli, J., Élez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T. M., Vidal, J., García, M. D. S., Viéitez, J. M., Páez, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx112 · Cited by 187 · see citing works
Analysis of KRAS / NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181 · see citing works
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Brea, E. J., Oh, C. Y., Manchado, E., Budhu, S., Gejman, R. S., Mo, G., Mondello, P., Han, J. E., Jarvis, C. A., Ulmert, D., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0177 · Cited by 170 · see citing works
Evaluation and prevention of diabetic neuropathy.
Aring, A. M., Jones, D. E., & Falko, J. M. (2005) · PubMed · Cited by 158 · see citing works
Management of oxaliplatin-induced peripheral neuropathy.
Saif, M. W., & Reardon, J. (2005) · PubMed Central · Cited by 148 · see citing works
Immunotherapy for Colorectal Cancer
Boland, P. M., & Ma, W. (2017) · Cancers · doi:10.3390/cancers9050050 · Cited by 148 · see citing works
BRAF Mutation in Colorectal Cancer: An Update: Supplementary Issue: Biomarkers for Colon Cancer
Barras, D. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25248 · Cited by 138 · see citing works
Colorectal Cancer Incidence Trends in the United States and United Kingdom: Evidence of Right- to Left-Sided Biological Gradients with Implications for Screening
Meza, R., Jeon, J., Renehan, A. G., & Luebeck, E. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4417 · Cited by 122 · see citing works
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
Normanno, N., Abate, R. E., Lambiase, M., Forgione, L., Cardone, C., Iannaccone, A., Sacco, A., Rachiglio, A. M., Martinelli, E., Rizzi, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx417 · Cited by 115 · see citing works
Age and Time as Factors in the Left-to-right Shift of the Subsite of Colorectal Adenocarcinoma: A Study of 213,383 Cases From the California Cancer Registry
Saltzstein, S. L., & Behling, C. A. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000225550.26751.6a · Cited by 113 · see citing works
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)
Aparicio, T., Lavau‐Denès, S., Phelip, J., Maillard, E., Jouve, J. L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv491 · Cited by 110 · see citing works
Older adults and cancer treatment
Given, B. A., & Given, C. W. (2008) · Cancer · doi:10.1002/cncr.23939 · Cited by 110 · see citing works
Programmed death-1 blockade in mismatch repair deficient colorectal cancer.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Azad, N. S., Laheru, D. A., Donehower, R. C., Crocenzi, T. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.103 · Cited by 106 · see citing works
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer
Figer, A., Perez‐Staub, N., Carola, É., Tournigand, C., Lledo, G., Flesch, M., Barceló, R., Cervantes, A., André, T., Colin, P., et al. (2007) · Cancer · doi:10.1002/cncr.23091 · Cited by 86 · see citing works
Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments
Owusu, C., Koroukian, S. M., SCHLUCHTER, M. D., Bakaki, P. M., & Berger, N. A. (2011) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2010.12.002 · Cited by 84 · see citing works
Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy
Ottaiano, A., Nappi, A. G., Tafuto, S., Nasti, G., Divitiis, C. D., Romano, C., Cassata, A., Casaretti, R., Silvestro, L., Avallone, A., et al. (2016) · Oncology · doi:10.1159/000442527 · Cited by 75 · see citing works
Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
Han, C., Li, F., Ma, J., & Zou, H. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.732159 · Cited by 71 · see citing works
The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4
Teixeira, M. C., Marques, D. F., Ferrari, A., Alves, M. F. S., Alex, A. K., Sabbaga, J., Hoff, P. M., & Riechelmann, R. P. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.09.010 · Cited by 64 · see citing works
Canadian cancer statistics at a glance: cancer in children
Ellison, L. F., De, P., Mery, L., et al. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081155 · Cited by 64 · see citing works
The relationship between tumour site, clinicopathological characteristics and cancer‐specific survival in patients undergoing surgery for colorectal cancer
Powell, A. G. M. T., Wallace, R., McKee, R. F., Anderson, J. H., Going, J. J., Edwards, J., & Horgan, P. G. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2012.03048.x · Cited by 62 · see citing works
Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial
Souglakos, J., Pallis, A. G., Kakolyris, S., Mavroudis, D., Androulakis, N., Kouroussis, C., Agelaki, S., Xenidis, N., Milaki, G., & Georgoulias, V. (2005) · Oncology · doi:10.1159/000089992 · Cited by 62 · see citing works
Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis
Wieten, E., Schreuders, E. H., Grobbee, E. J., Nieboer, D., Bramer, W. M., Lansdorp‐Vogelaar, I., Bruno, M. J., Kuipers, E. J., & Spaander, M. C. W. (2018) · Gut · doi:10.1136/gutjnl-2017-315340 · Cited by 61 · see citing works
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).
Kopetz, S., McDonough, S. L., Lenz, H.-J., Magliocco, A. M., Atreya, C. E., Diaz, L. A., Allegra, C. J., Raghav, K. P. S., Morris, V. K., Wang, S. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3505 · Cited by 58 · see citing works
The Effect of Diabetes on Oxaliplatin-Induced Peripheral Neuropathy
Uwah, A. N., Ackler, J. R., Leighton, J. C., Pomerantz, S. C., & Tester, W. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.05.002 · Cited by 51 · see citing works
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study
Sastre, J., Aranda, E., Massutí, B., Tabernero, J. M., Chaves-Conde, M., Abad, A., Carrato, A., Reina, J. J., Queralt, B., Gómez‐España, A., et al. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.11.002 · Cited by 50 · see citing works
Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer
Bendell, J. C., Ciardiello, F., Tabernero, J. M., Tebbutt, N. C., Eng, C., Bartolomeo, M. D., Falcone, A., Fakih, M., Kozloff, M. F., Segal, N. H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy208.003 · Cited by 50 · see citing works
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies
Ramanathan, R. K., Rothenberg, M. L., de Gramont, A., Tournigand, C., Goldberg, R. M., Gupta, S., & André, T. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp509 · Cited by 46 · see citing works
Right-sided vs left-sided colorectal cancer.
Venook, A. P. (2017) · PubMed · Cited by 33 · see citing works
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study
François, É., Berdah, J.-F., Chamorey, E., Lesbats, G., Teissier, E., Codoul, J.-F., Badetti, J.-L., Hébert, C., & Mari, V. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0681-2 · Cited by 31 · see citing works
Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer
Arkenau, H., Graeven, U., Kubicka, S., Grothey, A. F., Englisch-Fritz, C., Kretzschmar, A., Greil, R., Freier, W., Seufferlein, T. T. W., Hinke, A., et al. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.n.009 · Cited by 30 · see citing works
Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer
Cen, P., Liu, C., & Du, X. L. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr449 · Cited by 26 · see citing works
How to identify older patients with cancer who should benefit from comprehensive geriatric assessment?
Luce, S., Breucker, S. D., Gossum, A. V., Demols, A., Mekinda, Z., Ena, G., Kentos, A., Roumeguère, T., Ghanooni, R., Nouwynck, C., et al. (2012) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2012.06.003 · Cited by 18 · see citing works
KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers
Lee, K. H., Kim, J. S., Lee, C. S., & Kim, J. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23936 · Cited by 16 · see citing works
BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
Cutsem, E. V., Cuyle, P.-J. A., Huijberts, S. C. F. A., Schellens, J. H. M., Élez, E., Yaeger, R. D., Fakih, M., Montagut, C. O., Peeters, M., Desai, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy149.026 · Cited by 16 · see citing works
Result disclosure on ClinicalTrials. gov — first experiences and challenges
Minkenberg, R. (2010) · Pharmaceutical Programming · doi:10.1179/175709310x12845438122791 · Cited by 15 · see citing works
KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.
Diaz, L. A., Le, D. T., Yoshino, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.tps789 · Cited by 6 · see citing works
Reply to R. Obeid et al
Brasky, T. M., White, E., & Chen, C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4688 · Cited by 2 · see citing works
Association of diabetes with colorectal cancer treatment and outcomes.
Iyengar, A., Gold, H. T., Nicholson, J., & Becker, D. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e18112 · Cited by 1 · see citing works

Flagged first, then by citations

Sorted by citations

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer
Zhou, H., Zhu, L., Song, J. H., Wang, G., Li, P., Li, W., Luo, P., Sun, X., Wu, J., Liu, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01556-2 · Cited by 270 · see citing works
Probiotic strain Lactobacillus plantarum YYC-3 prevents colon cancer in mice by regulating the tumour microenvironment
Yue, Y., Ye, K., Lü, J., Wang, X., Zhang, S., Liu, L., Yang, B., Nassar, K. S., Xu, X., Pang, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110159 · Cited by 116 · see citing works
Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach
Rajpoot, K., & Jain, S. K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.132 · Cited by 103 · see citing works
TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development
Li, X.-S., Wu, Y., & Tian, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214436 · Cited by 82 · see citing works
TRP Channels in Digestive Tract Cancers
Stokłosa, P., Borgström, A., Kappel, S., & Peinelt, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051877 · Cited by 64 · see citing works
Synergistic therapy with tangeretin and 5-fluorouracil accelerates the ROS/JNK mediated apoptotic pathway in human colorectal cancer cell
Dey, D. K., Chang, S. N., Vadlamudi, Y., Park, J. G., & Kang, S. C. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111529 · Cited by 60 · see citing works
Immune characterization of metastatic colorectal cancer patients post reovirus administration
Parakrama, R. Y., Fogel, E. J., Chandy, C., Augustine, T. A., Coffey, M. C., Tesfa, L., Goel, S., & Maitra, R. (2020) · BMC Cancer · doi:10.1186/s12885-020-07038-2 · Cited by 52 · see citing works
RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition
Fang, L., Ford-Roshon, D., Russo, M., O’Brien, C., Xiong, X., Gurjao, C., Grandclaudon, M., Raghavan, S., Corsello, S. M., Carr, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30794-7 · Cited by 49 · see citing works
CPNE1 Enhances Colorectal Cancer Cell Growth, Glycolysis, and Drug Resistance Through Regulating the AKT-GLUT1/HK2 Pathway
Wang, Y., Pan, S., He, X., Wang, Y., Huang, H., Chen, J., Zhang, Y., Zhang, Z., & Qin, X. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s284211 · Cited by 37 · see citing works
Identification and Validation of Six Autophagy-related Long Non-coding RNAs as Prognostic Signature in Colorectal Cancer
Cheng, L., Han, T., Zhang, Z., Yi, P., Zhang, C., Zhang, S., & Peng, W. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.49449 · Cited by 35 · see citing works
Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 34 · see citing works
UCHL3 promotes proliferation of colorectal cancer cells by regulating SOX12 via AKT/mTOR signaling pathway.
Li, J., Yang, Z., Li, X., Dong, X., Chen, W., Guan, Z., & Zhang, C. (2020) · PubMed Central · Cited by 30 · see citing works
Mindfulness intervention, homogeneous medical concept, and concentrated solution nursing for colorectal cancer patients: a retrospective study
Feng, Y., Wang, K., Fan, J., Wu, X., Li, T., & Yang, Z. (2024) · BMC Cancer · doi:10.1186/s12885-024-12508-y · Cited by 26 · see citing works
“However, the current clinical nursing mode of homogeneous medical concept combined with focused solution mode lacks the ability to perceive the patient’s physiological state and enhance the patient’s sense of self-control [8].”
Peptides in Colorectal Cancer: Current State of Knowledge
Avilés‐Gaxiola, S., Gutiérrez‐Grijalva, E. P., León‐Félix, J., Angulo-Escalante, M. A., & Heredia, J. B. (2020) · Plant Foods for Human Nutrition · doi:10.1007/s11130-020-00856-6 · Cited by 25 · see citing works
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer
Cao, Y., Efetov, S. K., He, M., Fu, Y., Beeraka, N. M., Zhang, J., Zhang, X., Bannimath, N., & Chen, K. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00684-x · Cited by 24 · see citing works
Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-β Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p
Despotović, J., Dragičević, S., & Nikolić, A. (2021) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-021-00980-3 · Cited by 20 · see citing works
Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer
Batra, A., Rigo, R., Hannouf, M. B., & Cheung, W. Y. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.09.006 · Cited by 18 · see citing works
Self-citation
MicroRNA-Regulated Signaling Pathways: Potential Biomarkers for Pancreatic Ductal Adenocarcinoma
Mortoglou, M., Wallace, D., Djordjević, A. B., Djordjevic, V. R., Arısan, E. D., & Onganer, P. U. (2021) · Stresses · doi:10.3390/stresses1010004 · Cited by 17 · see citing works
Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy
Xu, M., Chang, J., Wang, W., Wang, X., Wang, X., Weng, W., Tan, C., Zhang, M., Ni, S., Wang, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.934083 · Cited by 16 · see citing works
Alisol A attenuates malignant phenotypes of colorectal cancer cells by inactivating PI3K/Akt signaling
Han, W., Xing, W., Wang, K., Wang, B., & Bai, K. (2022) · Oncology Letters · doi:10.3892/ol.2022.13369 · Cited by 14 · see citing works
LAMP2A overexpression in colorectal cancer promotes cell growth and glycolysis via chaperone‑mediated autophagy
Chen, R., Zhang, Y., Ge, Y., He, C., Wu, Z., Wang, J., Yu, J., Xiao, J., Zhang, X., Tao, M., et al. (2023) · Oncology Letters · doi:10.3892/ol.2023.14164 · Cited by 14 · see citing works
Real-World Use of Trifluridine/Tipiracil for Patients with Metastatic Colorectal Cancer in Canada
Samawi, H. H., Brezden‐Masley, C., Afzal, A. R., Cheung, W. Y., & Dolley, A. (2019) · Current Oncology · doi:10.3747/co.26.5107 · Cited by 14 · see citing works
Self-citation
LRIG3 represses cell motility by inhibiting slug via inactivating ERK signaling in human colorectal cancer
Zeng, K., Chen, X., Xu, M., Liu, X., Li, C., Xu, X., Pan, B., Qin, J., He, B., Pan, Y., et al. (2020) · IUBMB Life · doi:10.1002/iub.2262 · Cited by 13 · see citing works
Rab1A promotes cell proliferation and migration by upregulating Gli1 in colorectal cancer
Peng, C.-Z., Li, X., Ye, Z., & Wu, W. (2021) · Scientific Reports · doi:10.1038/s41598-021-95798-7 · Cited by 12 · see citing works
[Retracted] Mechanism of Gegen Qinlian Decoction Regulating ABTB1 Expression in Colorectal Cancer Metastasis Based on PI3K/AKT/FOXO1 Pathway
Li, F., Chen, L., Zheng, J., Yang, J., Song, X., Wang, Y., & Zhou, X. (2022) · BioMed Research International · doi:10.1155/2022/8131531 · Cited by 10 · see citing works
Retracted
Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored?
Silveira, M. J., Castro, F., Oliveira, M. J., & Sarmento, B. F. C. C. (2021) · Biomaterials Science · doi:10.1039/d1bm00137j · Cited by 10 · see citing works
Fractionated small cell‐free DNA increases possibility to detect cancer‐related gene mutations in advanced colorectal cancer
Ishida, Y., Takano, S., Maekawa, S., Yamaguchi, T., Yoshida, T., Kobayashi, S., Iwamoto, F., Kuno, T., Hayakawa, H., Matsuda, S., et al. (2020) · JGH Open · doi:10.1002/jgh3.12379 · Cited by 9 · see citing works
Hsa_circ_0001658 accelerates the progression of colorectal cancer through miR-590-5p/METTL3 regulatory axis
Lu, Y., Wang, X., Li, Z.-S., Wu, A., & Cheng, W.-X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i1.76 · Cited by 8 · see citing works
Sex differences in survival following surgery for esophageal cancer: A systematic review and meta-analysis
Liatsou, Ε., Bellos, I., Katsaros, I., Michailidou, S., Karela, N.-R., Mantziari, S., Rouvelas, I., & Schizas, D. (2024) · Diseases of the Esophagus · doi:10.1093/dote/doae063 · Cited by 8 · see citing works
Feasibility and safety of 0.6% sodium alginate in endoscopic submucosal dissection for colorectal neoplastic lesion: A pilot study
Nakamura, H., Morita, R., Ito, R., Sakurada, A., Tomita, N., Hirata, Y., Kanari, Y., Komatsu, Y., Takanashi, K., Anbo, T., et al. (2023) · DEN Open · doi:10.1002/deo2.313 · Cited by 7 · see citing works
TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma
Amin, N. D., Wang, H., Song, Q., Bhaskar, M., Yadav, S. P., Gilbert, M. R., Pant, H. C., Tabouret, É., & Zhuang, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411733 · Cited by 4 · see citing works
Proteogenomic biomarkers in colorectal cancers: clinical applications
Binetti, M., Lauro, A., Vaccari, S., Cervellera, M., & Tonini, V. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1782202 · Cited by 4 · see citing works
Compound 275# Induces Mitochondria-Mediated Apoptosis and Autophagy Initiation in Colorectal Cancer Cells through an Accumulation of Intracellular ROS
Yang, D., Li, Y., Ma, S.-Q., Zhang, Y., Huang, J., & He, L. (2023) · Molecules · doi:10.3390/molecules28073211 · Cited by 3 · see citing works
Current Perspective and Treatment Strategies in Targeted Therapy for Colorectal Cancer
Maurya, P. K., & Mani, A. (2024) · Clinical Cancer Drugs · doi:10.2174/012212697x308365240529100442 · Cited by 3 · see citing works
Pyrrolyldihydropyrazino[1,2-a]indoletrione Analogue Microtubule Inhibitor Induces Cell-Cycle Arrest and Apoptosis in Colorectal Cancer Cells
Yang, D., Qin, H.-X., Zhang, N.-N., Zhang, Y.-J., Huang, J., Hu, C., Zhang, X., Li, Y., & He, L. (2023) · Molecules · doi:10.3390/molecules28041948 · Cited by 3 · see citing works
CopA3 treatment suppressed multidrug resistivity in HCT-116 cell line by p53-induced degradation of hypoxia-inducible factor 1α
Dey, D. K., Gahlot, H., Chang, S. N., & Kang, S. C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121933 · Cited by 2 · see citing works
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis
Sousa, M. J., Gomes, I. F., Pereira, T. C., Magalhães, J. C., Basto, R., de Paulo, J. V., Jacinto, P., Bonito, N., & Sousa, G. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100531 · Cited by 2 · see citing works
Gene and cytokine expression profiles of metastatic colorectal cancer patients post reovirus administration
Zweig, V., Goel, S., & Maitra, R. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i2.113428 · Cited by 1 · see citing works
HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
Fraga, T., Sousa, M. J., Magalhães, J. C., Basto, R., de Paulo, J. V., Bonito, N., Magalhães, J. P., Figueiredo, P., & SOUSA, G. M. C. D. (2023) · Cureus · doi:10.7759/cureus.42536 · Cited by 1 · see citing works
Unusual case of colorectal carcinoma with sarcoid-like mediastinal adenopathy and near-fatal DPD deficiency
Pillay, S., Terreblanche, O. D., Devar, J. W., & Wadee, A. (2021) · South African Journal of Oncology · doi:10.4102/sajo.v5i0.160 · Cited by 1 · see citing works
Optimized Algebraic Reconstruction Algorithm Based Hemodynamic Changes in Color Doppler Ultrasound in Monitoring the Patients with Colorectal Cancer Undergoing Peripherally Inserted Central Catheter and Catheterization Nursing
Yu, M., Li, J., Li, Y., & Yu, L. (2021) · Scientific Programming · doi:10.1155/2021/8375290
Encorafenib (Braftovi)
Reimbursement Team (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.152
Prognostic value of Gli1 expression on colorectal cancer: a retrospective study
Zhang, Z., Chen, J., Ma, Y., Wang, W., Xiao, Y., & Ma, D. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04918-y
Lesion Volume Divided by ADC Measures Is an Independent Prognostic Marker in Colorectal Liver Metastasis Treated by Y90-radioembolization
Heitmann, F., Surov, A., Christ, S. M., March, C., Pech, M., Thormann, M., & Damm, R. (2024) · In Vivo · doi:10.21873/invivo.13827
Burden of Colorectal Cancer in Northeastern Iran in 2019: A Cross-Sectional Study
Jafarabadi, Z., Hasani, H., & Sadr, M. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02086-w
Additional file 1 of Immune characterization of metastatic colorectal cancer patients post reovirus administration
Parakrama, R., Fogel, E. J., Chandy, C., Augustine, T. A., Coffey, M., Tesfa, L., Goel, S., & Maitra, R. (2020) · Figshare · doi:10.6084/m9.figshare.12510866
Responsible Artificial Intelligence : Designing Frameworks for Ethical, Sustainable, and Risk-Aware Practices
Haidar, A. (2024) · theses.fr (ABES) · doi:10.70675/bee40239z04e9z4bedz9dafz562ce0fcc4c1

The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
Moorcraft, S. Y., Smyth, E. C., & Cunningham, D. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13491797 · Cited by 34 · see citing works
The changing face of treatment for metastatic colorectal cancer
Pfeiffer, P., Köhne, C.-H., & Qvortrup, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1543593 · Cited by 12 · see citing works
Treatment of Metastatic Colorectal Cancer: Beyond Progression
Güren, A. K., & Köstek, O. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004840
A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer.
Weinberg, B. A., Marshall, J. L., Hartley, M. L., & Salem, M. E. (2016) · PubMed · Cited by 9 · see citing works
Recent advances in personalized colorectal cancer research
Kraus, S. R., Nabiochtchikov, I., Shapira, S., & Arber, N. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.025 · Cited by 55 · see citing works

Authors: Yu, I. S., & Cheung, W. Y.
Affiliations: University of British Columbia (CA)
University of Calgary (CA)
Corresponding author: Cheung, Winson Y.
ORCID: Yu, Irene S.
Cheung, Winson Y.
Venue: Canadian Journal of Gastroenterology and Hepatology
Publisher: Wiley
Published: 2018-11-05
Volume: 2018
Pages: 1-11
ISSN: 2291-2789 (ISSN-L)
2291-2797
DOI: 10.1155/2018/9450754
PMC: PMC6241232
OpenAlex: W2899794928
Cited by: 47
References: 108
Citations by year: 2026: 2 · 2025: 1 · 2024: 5 · 2023: 9 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 1
FWCI: 0.60
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Canadian Journal of Gastroenterology and Hepatology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, personalized medicine, systemic therapy, biomarkers, fluoropyrimidine chemotherapy, irinotecan, oxaliplatin, anti-VEGF therapy, anti-EGFR therapy, treatment selection
MeSH terms: Clinical Decision-Making, Canada, Humans, Medical Oncology, Neoplasm Metastasis, Biomarkers, Tumor, Colorectal Neoplasms, Incidence, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks